Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Published on by Oncology

Dr. Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Clinical Physician | Shizuoka General Hospital | Japan

Dr. Kimihide Kusafuka is a distinguished pathologist at Shizuoka General Hospital, Japan, internationally recognized for his expertise in head and neck pathology, salivary gland tumors, and molecular oncopathology. His research has been instrumental in redefining diagnostic criteria, histopathological classifications, and gene alteration profiles across a spectrum of rare and aggressive neoplasms. Dr. Kusafuka has contributed significantly to the understanding of salivary duct carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, and solitary fibrous tumors through large-cohort analyses, multi-institutional collaborations, and advanced molecular techniques, including MYB/MYBL1 rearrangement characterization, CRTC1/3-MAML2 fusion analysis, and the identification of novel tumor variants. His scholarly output comprises 100 peer-reviewed documents, reflecting a sustained commitment to translational pathology and precision diagnostics. With more than 380 collaborators worldwide, his work has shaped global guidelines, influenced tumor classification systems, and improved prognostic assessment models for clinicians and researchers in the field. Dr. Kusafuka’s studies spanning molecular pathology, surgical pathology, and carcinoma outcome prediction—continue to strengthen diagnostic accuracy and therapeutic decision-making, ultimately improving patient outcomes and contributing to the advancement of cancer pathology. His rigorous methodologies, cross-disciplinary partnerships, and leadership in multi-center Japanese cohorts highlight his role as a leading figure in contemporary oncologic pathology. Dr. Kusafuka’s academic influence and research productivity are reflected in his metrics: 1,768 citations, 100 documents, and an h-index of 25.

Profiles: Scopus| ORCID | ResearchGate

Featured Publications

Kusafuka, K., et al. (2022). A symptomatic intercalated duct lesion of the parotid gland: A case report with immunohistochemical and genetic analyses. Medical Molecular Morphology. Citations: 2

Kusafuka, K., et al. (2022). Salivary gland polymorphous adenocarcinoma: Clinicopathological features and gene alterations in 36 Japanese patients. Journal of Oral Pathology and Medicine.Citations: 6

Kusafuka, K., et al. (2022). Intraoral basal cell carcinoma of the soft palate: A diagnostic pitfall. Citations: 2

Kusafuka, K., et al. (2022). The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: Multi-institutional retrospective analysis in Japan. Head & Neck.  Citations: 12

Kusafuka, K., et al. (2022). Salivary mucoepidermoid carcinoma: Histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features. Histopathology. Citations: 28

George Kroumpouzos | Skin Oncology | Editorial Board Member

Published on by Oncology

Prof. Dr. George Kroumpouzos | Skin Oncology | Editorial Board Member

Professor | Jundiai Medical School, Brazil / Alpert Medical School of Brown University, USA |  United States

Dr. George Kroumpouzos is an internationally recognized dermatologist affiliated with The Warren Alpert Medical School of Brown University, United States, known for his extensive contributions to medical, surgical, cosmetic, and psychocutaneous dermatology, with a strong recent focus on the integration of artificial intelligence, large language models, and virtual reality into diagnostic and therapeutic practices. He has authored 162 peer-reviewed publications, covering clinically significant topics such as counterfeit botulinum toxin and cosmetic iatrogenic botulism, Er:YAG laser therapy for vulvovaginal atrophy in breast cancer survivors, exosome-based treatments for pattern hair loss, AI-driven innovations in maternal–fetal dermatology, and advanced nonsurgical rhinoplasty techniques. His broad collaborative network spanning more than 200 researchers globally highlights his commitment to interdisciplinary advancement across dermatology, aesthetic medicine, oncology, psychology, and women’s health. Dr. Kroumpouzos’s scholarly work consistently promotes patient safety, diagnostic accuracy, and equitable access to cutting-edge dermatologic care, positioning him as a leading voice in regulatory reform and digital transformation within the field. His global impact is underscored by his ability to bridge clinical insight with emerging technologies, shaping future standards and addressing diverse patient needs across populations. Dr. Kroumpouzos’s academic influence and research productivity are reflected in his metrics: 2,695 citations, 162 documents, and an h-index of 28.

profiles: Scopus| ORCID | ResearchGate

Featured Publications

Türk, C. B., Mirza, F. N., & Kroumpouzos, G. (2023). A screening proposal for Zoom dysmorphia in virtual settings. Life, 13(8), Article 1678.

Bhargava, S., Yumeen, S., Henebeng, E., & Kroumpouzos, G. (2022). Erosive pustular dermatosis: Delving into etiopathogenesis and management. Life, 12(12), Article 2097.

Kroumpouzos, G., Paroikaki, M. E., Yumeen, S., Bhargava, S., & Mylonakis, E. (2022). Cutaneous complications of mRNA and AZD1222 COVID-19 vaccines: A worldwide review. Microorganisms, 10(3), Article 624.

Das, K., Daveluy, S., Kroumpouzos, G., Agarwal, K., Podder, I., Farnbach, K., Ortega-Loayza, A. G., Szepietowski, J. C., Grabbe, S., & Goldust, M. (2022). Efficacy and toxicity of classical immunosuppressants, retinoids and biologics in hidradenitis suppurativa. Journal of Clinical Medicine, 11(3), Article 670.

Messas, T., Messas, A., & Kroumpouzos, G. (2021). Carbon dioxide laser vulvovaginal rejuvenation: A systematic review. Cosmetics, 8(3), Article 56.

Xin Yi Foong | Breast Cancer | Best Researcher Award

Published on by Oncology

Ms. Xin Yi Foong | Breast Cancer | Best Researcher Award

Core Surgical Trainee | Mid Yorkshire Teaching NHS Trust | United Kingdom

Dr Xin Yi Foong is a clinical researcher in Plastic and Reconstructive Surgery whose academic work is centred on improving the safety, accuracy, and reliability of autologous breast reconstruction through quantitative imaging and evidence-based microsurgical innovation. Her research explores the use of indocyanine green (ICG) fluorescence imaging to guide intraoperative evaluation of mastectomy flap perfusion, with particular emphasis on establishing objective perfusion scoring methods that support consistent, data-guided surgical decisions. Her published study in the Journal of Plastic, Reconstructive & Aesthetic Surgery introduced a structured quantitative perfusion algorithm that demonstrated strong discriminatory capability in identifying poorly perfused tissue and informing reconstructive planning, offering evidence that aligns with national quality frameworks and enhances postoperative outcomes. Alongside this work, she is investigating postoperative monitoring strategies in DIEP flap reconstruction, assessing early-phase observation models that preserve patient safety while promoting efficient and clinically coherent perioperative pathways. Her wider academic activity includes outcome audits, service-improvement initiatives, and reconstructive pathway analyses, all aimed at refining surgical workflows through quantitative measures, imaging-based assessment, and rigorous postoperative metrics. Conducted within multidisciplinary teams of plastic surgeons, anaesthetists, and breast specialists, her research supports the translation of imaging-derived insights into routine clinical practice. Through a growing publication profile, an active ORCID research identity, and sustained commitment to scientifically grounded surgical advancement, Dr Foong contributes to the development of reproducible, clinically meaningful, and patient-centred innovations that strengthen microsurgical dependability and elevate the overall quality of care within reconstructive breast surgery.

Profiles: Scopus | ORCID

Featured Publications

1. Foong, X. Y., Williamson, A., Lymperopoulos, N., & Holmes, W. J. M. (2025). Does indocyanine green imaging perfusion scoring reduce mastectomy flap necrosis in immediate autologous breast reconstruction? A single-centre cohort study. Journal of Plastic, Reconstructive & Aesthetic Surgery, 111, 198–206.

2. Foong, X. Y., Williamson, A., Lymperopoulos, N., & Holmes, W. J. M. (2025). Does intraoperative indocyanine green (ICG) reduce the outcome of mastectomy skin flap necrosis in patients undergoing immediate breast reconstruction? European Journal of Surgical Oncology. Advance online publication. 

Gerardo Rosati | Breast Cancer | Best Researcher Award

Published on by Oncology

Dr. Gerardo Rosati | Breast Cancer | Best Researcher Award

Azienda Ospedaliera San Carlo di Potenza | Italy

Dr. Gerardo Rosati is a distinguished Italian medical oncologist whose career reflects over three decades of sustained clinical practice, research leadership, and commitment to advancing evidence-based cancer care. Laureato con lode all’Università “Federico II” di Napoli e successivamente specializzato in Oncologia presso la Seconda Università di Napoli, ha sviluppato precocemente un interesse scientifico per i markers tumorali e per l’innovazione terapeutica nei tumori solidi. La sua formazione è stata arricchita da numerose borse di studio FIRC, ESO e Fondazione Lina Belli, che gli hanno consentito di partecipare a corsi avanzati internazionali su colon-retto, neuro-oncologia, recidive ginecologiche, terapia antalgica e strategie emergenti in oncologia medica. Dal 1998 opera stabilmente presso l’U.O. di Oncologia Medica dell’Azienda Ospedaliera “S. Carlo” di Potenza, dove ha assunto ruoli via via più qualificati fino alla responsabilità del coordinamento dell’attività di ricerca clinica. La sua attività come sperimentatore in oltre cento studi clinici di fase I–III e in numerosi progetti osservazionali riguarda chemioterapie innovative, farmaci biologici, anti-EGFR, anti-angiogenici, immunoterapia, tossicità correlate ai trattamenti e biomarcatori predittivi. Ha inoltre svolto un’intensa attività di revisione scientifica per riviste internazionali e per enti accademici e sanitari nazionali, contribuendo al miglioramento della qualità metodologica della ricerca oncologica. Membro attivo di AIOM, ESMO ed ESO College, promuove l’integrazione tra clinica, ricerca e formazione, con un impatto significativo sui percorsi assistenziali nei tumori gastrointestinali e in altre neoplasie solide. His academic influence is reflected in 2,813 citations, 123 documents, and an h-index of 27, underscoring his meaningful contributions to contemporary clinical oncology.

Profiles: Scopus | ORCID

Featured Publications

1. Rosati, G., De Stefano, A., Restivo, A., Fanotto, V., Cicero, G., Colombo, A., Dell’Aquila, E., Parisi, A., Ortolani, S., Lutrino, S. E., Carlomagno, C., Dapoto, F., Reggiardo, G., Tonetto, F., Ravo, V., Aprile, G., Bilancia, D., Avallone, A., Romano, C., Argiolas, V., & Giovinazzo, G. (2026). Short-Course Radiotherapy for Older Patients with Locally Advanced Rectal Cancer and Unfit for Chemotherapy: The SOFT Study. Radiotherapy and Oncology.

2. Rosati, G., Piccirillo, M. C., Nasti, G., De Stefano, A., Carlomagno, C., Romano, C., Cassata, A., Silvestro, L., Nappi, A., Perrone, F., Budillon, A., & Avallone, A. (2025). A Post Hoc Analysis of Older Patients with Metastatic Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy Plus Bevacizumab: The Randomized Obelics Study. Drugs & Aging, 1–10.

3. Avallone, A., Giuliani, F., De Stefano, A., Santabarbara, G., Nasti, G., Montesarchio, V., Rosati, G., Cassata, A., Leo, S., Romano, C., Tamburini, E., Silvestro, L., Lotesoriere, C., Nappi, A., Santini, D., Petrillo, A., Colombo, A., Febbraro, A., Leone, A., Mannavola, F., & Laterza, M. M. (2024). Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial. Journal of Clinical Oncology, 43(7), 829–839.

4. Montrone, M., Rosati, G., Longo, V., Catino, A., Massafra, R., Nardone, A., Pesola, F., Montagna, E. S., Marech, I., & Pizzutilo, P. (2023). Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. Journal of Clinical Medicine, 12(5), 1833.

5. Rosati, G., Montrone, M., Pacilio, C., Colombo, A., Cicero, G., Paragliola, F., Vaia, A., Annunziata, L., & Bilancia, D. (2022). An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer. Journal of Clinical Medicine, 11(23), 7108.

Aminah Alotaibi | Breast Cancer | Best Researcher Award

Published on by Oncology

Dr. Aminah Alotaibi | Breast Cancer | Best Researcher Award

Assistant Research Professor | King Abdulaziz city for science and technology | Saudi Arabia

Dr. Aminah Ghazi Alotaibi is a distinguished researcher affiliated with the King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. With a Scopus h-index of 3, 4 indexed publications, and 58 citations, she has demonstrated consistent scholarly impact in the fields of hematology, stem cell biology, and molecular diagnostics. Her research primarily focuses on elucidating the phenotypic and molecular diversity of hematopoietic stem and progenitor cells (HSPCs) derived from cord blood and bone marrow, advancing the understanding of their biological significance and translational potential in clinical applications. Notably, her recent open-access article titled “Distinct Phenotypic and Molecular Characteristics of CD34− and CD34+ Hematopoietic Stem/Progenitor Cell Subsets in Cord Blood and Bone Marrow Samples: Implications for Clinical Applications” (2025, Diagnostics) highlights her expertise in cellular characterization and regenerative medicine, offering valuable insights for stem cell-based therapies and transplantation science. Dr. Alotaibi’s collaborative network spans 23 co-authors, reflecting her active engagement in multidisciplinary and international scientific research. Her work integrates clinical hematology, genomics, and translational biomedical research, bridging the gap between laboratory discoveries and patient-centered innovations. Through her contributions, she aims to enhance diagnostic precision, therapeutic efficacy, and personalized medical approaches in hematologic and immune-related disorders. Dr. Alotaibi’s scholarly endeavors not only strengthen Saudi Arabia’s presence in global biomedical research but also contribute to the broader scientific community’s understanding of stem cell biology and its clinical potential.

Profiles: Google Scholar | Scopus | ORCID | LinkedIn

Featured Publications

1. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2021). Tumour necrosis factor-α (TNF-α) enhances dietary carcinogen-induced DNA damage in colorectal cancer epithelial cells through activation of JNK signaling pathway. Toxicology, 457, 152806. Cited by: 36

2. Al-Saleh, I., Elkhatib, R., Al-Rajoudi, T., Al-Qudaihi, G., Manogarannogaran, P., Alotaibi, A. G., & others. (2020). Cytotoxic and genotoxic effects of e-liquids and their potential associations with nicotine, menthol and phthalate esters. Chemosphere, 249, 126153. Cited by: 22

3. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2023). Tumour necrosis factor-alpha (TNF-α)-induced metastatic phenotype in colorectal cancer epithelial cells: Mechanistic support for the role of microRNA-21. Cancers, 15(3), 627. Cited by: 21

4. Gaafar, A., Hamza, F. N., Yousif, R., Shinwari, Z., Alotaibi, A. G., Iqniebi, A., & others. (2025). Distinct phenotypic and molecular characteristics of CD34− and CD34+ hematopoietic stem/progenitor cell subsets in cord blood and bone marrow samples: Implications for clinical applications. Diagnostics, 15(4), 447. Cited by: 1

5. Alotaibi, A. G. (2023). Effect of the inflammatory mediator TNF-α on colorectal cancer epithelial cells development and metastasis, role of dietary carcinogens and miRNA [Doctoral dissertation, Imperial College London]. Imperial College Repository.

Dr. Aminah Ghazi Alotaibi’s research advances global understanding of inflammation-driven carcinogenesis and stem cell biology, bridging molecular insights with clinical translation. Her work contributes to precision oncology, regenerative medicine, and the development of safer therapeutic strategies, fostering innovation that benefits both scientific progress and human health worldwide.

Mirjana Popadić | Carcinoma | Best Researcher Award

Published on by Oncology

Dr. Mirjana Popadić | Carcinoma | Best Researcher Award

Dermatovenerologist-Oncologist | Medigroup | Serbia

Dr. Mirjana Popadić is a distinguished researcher and faculty member at the University of Belgrade, Serbia, with a strong academic and clinical focus on dermatology, particularly in the diagnostic and histopathological evaluation of skin lesions. Over the course of her career, she has contributed significantly to the advancement of dermatological science, with 15 published research documents and over 121 citations, reflecting her growing influence within the global dermatology research community. Her work bridges the gap between clinical practice and experimental dermatopathology, with a special emphasis on innovative diagnostic techniques such as vertical ex vivo dermoscopy, a promising approach for improving the accuracy and differentiation of cutaneous lesions. Dr. Popadić’s research output, characterized by methodological precision and translational value, underscores her commitment to enhancing diagnostic reliability and patient outcomes in dermatologic oncology and inflammatory skin diseases. With an h-index of 7, her studies have been cited and utilized by peers across multiple institutions, demonstrating her active engagement in international scholarly collaboration. She has co-authored with nine other researchers, reflecting her interdisciplinary approach and contribution to collective scientific advancement. As a representative of the University of Belgrade, Dr. Popadić’s work not only reinforces Serbia’s academic presence in global dermatological research but also provides essential insights into the development of evidence-based diagnostic methodologies. Her scholarly contributions, teaching involvement, and clinical expertise together form a robust academic profile dedicated to the pursuit of excellence in skin pathology research, medical education, and healthcare innovation.

Profiles: Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Popadić, M., Brasanac, D., Milošev, D., Ravić Nikolić, A., & Mitrović, S. (2024). Vertical ex vivo dermoscopy in assessment of malignant skin lesions. Biomedicines, 12(8), 1683.

2. Popadić, M. (2018). Dermatoscopy of multiple piloleiomyomas with disseminated and segmental distribution. Indian Journal of Dermatology, Venereology and Leprology.

3. Popadić, M. (2018). Cutaneous polyarteritis nodosa: Uncommon and rare form of cutaneous vasculitis. Serbian Journal of Dermatology and Venereology, 10(2), 65–70.

4. Popadić, M. (2017). The significance of blue color in dermatoscopy. Journal der Deutschen Dermatologischen Gesellschaft (JDDG).

5. Popadić, M. (2016). Dermatoscopy in diagnosing maculopapular cutaneous mastocytosis. Praxis Medica.

Dr. Mirjana Popadić’s research advances the precision and reliability of dermatological diagnostics through innovative dermoscopic and histopathological techniques. Her contributions enhance early detection of malignant and rare skin disorders, bridging clinical practice and research to improve patient outcomes and promote global standards in dermatologic oncology.

Omar Alqaisi | Skin Cancer | Best Researcher Award

Published on by Oncology

Mr. Omar Alqaisi | Skin Cancer | Best Researcher Award

Al-Zaytoonah University of Jordan | Jordan

Dr. Omar M. Alqaisi is a dedicated academic and researcher at Al-Zaytoonah University of Jordan whose scholarly contributions reflect a strong commitment to advancing healthcare through evidence-based nursing practice and oncology research. With 11 published documents, 46 citations, and an h-index of 3, his work demonstrates a consistent trajectory of academic growth and increasing impact in the fields of clinical nursing, psycho-oncology, and patient-centered care. His notable publication, “A Narrative Review of the Roles of Nursing in Addressing Sexual Dysfunction in Oncology Patients,” underscores his focus on addressing sensitive and underexplored areas of oncology, particularly the psychosocial and emotional well-being of cancer patients, while emphasizing the indispensable role of nurses in holistic recovery and improving quality of life. A hallmark of his career is his emphasis on interdisciplinary collaboration, evidenced by co-authorship with more than 100 researchers across multiple disciplines, reflecting his ability to foster teamwork and integrate diverse perspectives to address complex healthcare challenges. His research is characterized by analytical precision, ethical grounding, and a human-centered approach, aligning with global healthcare trends that prioritize compassion, inclusivity, and evidence-based interventions. Beyond individual studies, Dr. Alqaisi’s work contributes to the broader advancement of nursing education, clinical practice, and patient advocacy in oncology. His growing academic influence positions him as an emerging leader within regional and international research communities. With continued development in empirical methodologies, digital health innovations, and cross-cultural healthcare models, he is poised to expand his contributions to global nursing and oncology discourse. Dr. Alqaisi’s research not only advances academic understanding but also creates meaningful societal impact by emphasizing empathy, communication, and the integration of psychosocial care into clinical frameworks, exemplifying a new generation of scholars committed to bridging scientific innovation with humanistic healthcare practice.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

1. Tai, P., Alqaisi, O., Al-Ghabeesh, S., Sijarina, L., Yu, E., Thachuthara, A. J., Assouline, A., Souied, O., Hagel, K., & Joseph, K. (2025, October 9). Immune checkpoint inhibitors in Merkel cell carcinoma of the skin: A 2025 comprehensive review. Cancers, 17(19), 3272.

2. Alqaisi, O., Al-Ghabeesh, S., Tai, P., Wong, K., Joseph, K., & Yu, E. (2025, August 14). A narrative review of the roles of nursing in addressing sexual dysfunction in oncology patients. Current Oncology, 32(8), 457.

3. Tai, P., Alqaisi, O., Al-Ghabeesh, S., Sijarina, L., Yu, E., Thachuthara, A. J., Assouline, A., Souied, O., Hagel, K., & Joseph, K. (2025, July 25). Immunotherapy in Merkel cell carcinoma of the skin: A 2025 comprehensive review. Preprints, 202507.2063.v1.

4. Alqaisi, O., Subih, M., Joseph, K., Yu, E., & Tai, P. (2025, June). Oncology nurses’ attitudes, knowledge, and practices in providing sexuality care to cancer patients: A scoping review. Current Oncology, 32(6), 337.

5. Alqaisi, O. M., & Al-Ghabeesh, S. (2024, July 31). Quality of postoperative pain management in orthopedic patients and its impact on sleep quality and patient satisfaction: An integrative review. Cureus, 16(7), e65872.

Dr. Omar M. Alqaisi’s research advances the integration of compassionate, evidence-based nursing within oncology care, addressing both clinical and psychosocial patient needs. His work strengthens global healthcare practices by promoting interdisciplinary collaboration, enhancing patient quality of life, and shaping innovative models for holistic, human-centered medical care.

Melissa Christiaens | Cervical Cancer | Best Researcher Award

Published on by Oncology

Dr. Melissa Christiaens | Cervical Cancer | Best Researcher Award

Radiation-Oncology | University Hospitals Leuven | Belgium

Dr. Melissa Christiaens is a highly accomplished Radiation Oncologist recognized for her contributions to the advancement of radiotherapy and clinical oncology research. With extensive experience in oncological treatment, she has played a key role in integrating evidence-based radiotherapy techniques into modern cancer care. Her professional expertise spans across radiotherapy quality assurance, pediatric oncology, gynecologic cancers, and multidisciplinary tumor management. As an active member of several leading scientific organizations—including the European Society for Radiotherapy and Oncology, the Paediatric Radiation Oncology Society, the European Society of Gynaecological Oncology, the EuroEwing Consortium, and the Connective Tissue Oncology Society—she consistently collaborates in large-scale international research networks to improve patient outcomes and optimize therapeutic protocols. Her research interests focus on clinical trials in radiotherapy, immuno-oncology integration, and precision treatment strategies for rare and complex cancers. Dr. Christiaens has contributed to numerous high-impact peer-reviewed journals such as The Lancet, Radiotherapy and Oncology, BMC Cancer, and Gynecologic Oncology, where her publications have enhanced the scientific understanding of cancer treatment outcomes, safety, and innovation. Her research skills encompass clinical data interpretation, protocol development, treatment optimization, and evidence synthesis—supported by her commitment to maintaining the highest standards of clinical excellence. Throughout her career, she has demonstrated exceptional leadership in oncology research and education, promoting collaboration and innovation within the global cancer research community. Her achievements continue to inspire advancements in patient-centered cancer therapy and clinical radiobiology. Her enduring scientific legacy is reflected through 1,417 citations, 25 documents, and an h-index of 12, underscoring her influential role in advancing the frontiers of clinical radiotherapy, oncology innovation, and multidisciplinary cancer research.

Profiles: Google Scholar | Scopus | ResearchGate

Featured Publications

1. Pötter, R., Tanderup, K., Schmid, M. P., Jürgenliemk-Schulz, I., Haie-Meder, C., & Christiaens, M., et al. (2021). MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): A multicentre prospective cohort study. The Lancet Oncology, 22(4), 538–547. Cited by: 613

2. Zhang, H., Ahearn, T. U., Lecarpentier, J., Barnes, D., Beesley, J., Qi, G., Jiang, X., & Christiaens, M., et al. (2020). Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 52(6), 572–581. Cited by: 466

3. Lorusso, D., Xiang, Y., Hasegawa, K., Scambia, G., Leiva, M., Ramos-Elias, P., & Christiaens, M., et al. (2024). Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18). The Lancet, 404(10460), 1321–1332. 
Cited by: 323

4. Ajithkumar, T., Horan, G., Padovani, L., Thorp, N., Timmermann, B., Alapetite, C., & Christiaens, M., et al. (2018). SIOPE–Brain tumor group consensus guideline on craniospinal target volume delineation for high-precision radiotherapy. Radiotherapy and Oncology, 128(2), 192–197. Cited by: 113

5. De Ruysscher, D., Sharifi, H., Defraene, G., Kerns, S. L., & Christiaens, M., et al. (2013). Quantification of radiation-induced lung damage with CT scans: The possible benefit for radiogenomics. Acta Oncologica, 52(7), 1405–1410. Cited by: 74

Permal Deo | Prostate Cancer | Best Researcher Award

Published on by Oncology

Dr. Permal Deo | Prostate Cancer | Best Researcher Award

Senior Lecturer | Clinical and Health Sciences, University of South Australia | Australia

Dr. Permal Deo is a distinguished food scientist and academic leader renowned for his contributions to nutrition, food biochemistry, and public health research. He holds a PhD in Food Biochemistry from Queen’s University Belfast, UK, where his doctoral work investigated the effects of food-derived advanced glycation end-products (AGEs) on oxidative stress and receptor activity in human cell lines. Complementing this, he earned a Master of Applied Science and Postgraduate Diploma from The University of Queensland, Australia, and a Bachelor of Science from The University of the South Pacific, Fiji. With over two decades of academic, research, and industry experience, Dr. Deo’s expertise encompasses food microbiology, food processing, functional foods, and the molecular pathways linking type 2 diabetes and Alzheimer’s disease. His research emphasizes the bioactivity of natural plant compounds and nutraceuticals in combating oxidative stress and inflammation, as well as the antimicrobial and food safety applications of electrochemically activated solutions. An accomplished mentor and research leader, he has supervised numerous postgraduate students and attracted more than AUD 2.5 million in competitive funding from prestigious bodies including the Australian Research Council, Diabetes Australia, and Horticulture Innovation. His extensive collaborations with institutions such as CSIRO, Monash University, and the University of Adelaide have advanced understanding in genome stability, indigenous food systems, and sustainable nutrition technologies. Widely recognized for his scholarly impact and leadership, Dr. Deo has presented at global scientific conferences and published influential studies in leading journals. His enduring scientific legacy is reflected through 944 citations, 57 documents, and an h-index of 19, underscoring his influential role in advancing the frontiers of food biochemistry, nutritional science, and biomedical innovation.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Snelson, M., Tan, S. M., Clarke, R. E., De Pasquale, C., Thallas-Bonke, V., Deo, P., … & Coughlan, M. T. (2021). Processed foods drive intestinal barrier permeability and microvascular diseases. Science Advances, 7(14), eabe4841. Cited by: 148

2. Sim, D. P., Khazandi, M., Chan, W. Y., Deo, P., & Trott, D. J. (2019). Antimicrobial activity of thyme oil, oregano oil, thymol and carvacrol against sensitive and resistant microbial isolates from dogs with otitis externa. Veterinary Dermatology. Cited by: 106

3. Deo, P., Hewawasam, E., Karakoulakis, A., Claudie, D. J., Nelson, R., & Vemulpad, S. (2016). In vitro inhibitory activities of selected Australian medicinal plant extracts against protein glycation, angiotensin converting enzyme (ACE), and digestive enzymes linked to diabetes. BMC Complementary and Alternative Medicine, 16(1), 435. Cited by: 61

4. Bergamin, A., Mantzioris, E., Cross, G., Deo, P., Garg, S., & Hill, A. M. (2019). Nutraceuticals: Reviewing their role in chronic disease prevention and management. Pharmaceutical Medicine, 33(4), 291–309. Cited by: 60

5. Fenech, M., Knasmueller, S., Knudsen, L. E., Kirsch-Volders, M., Deo, P., … & Bonassi, S. (2021). “Micronuclei and Disease” special issue: Aims, scope, and synthesis of outcomes. Mutation Research/Reviews in Mutation Research, 788, 108384. Cited by: 54

6. Ferro, S., Amorico, T., & Deo, P. (2018). Role of food sanitising treatments in inducing the ‘viable but nonculturable’ state of microorganisms. Food Control, 91, 321–329. Cited by: 54

Ramon Mangues | Cancer | Best Research Article Award

Published on by Oncology

Prof. Dr. Ramon Mangues | Cancer | Best Research Article Award

Pharmacological Research | Institut de Recerca Sant Pau | Spain

Prof. Dr. Ramon Mangues Bafalluy, PharmD, PhD, is a distinguished Clinical Pharmacist and Biomedical Research Professor at the Institut de Recerca, Hospital de la Santa Creu i Sant Pau, where he leads the Consolidated Oncogenesis and Antitumor Drugs Group (GOA). A recognized authority in oncology, nanomedicine, and targeted drug delivery, he has made pioneering contributions to the development of therapeutic nanotechnologies and translational cancer research. Trained in pharmacy and clinical pharmacology, Dr. Mangues advanced his expertise in cancer biology through extensive postdoctoral research at the New York University Medical Center. His professional career spans key leadership roles within IIB Sant Pau, CIBER-BBN, and as Co-founder and Scientific Advisor of Nanoligent S.L., a spin-off dedicated to translating nanomedicine discoveries into clinical therapies. His research interests encompass nanoconjugates, protein-based nanoparticles for targeted drug delivery, immunotherapeutic strategies, preclinical drug development, and biomarker identification for improved cancer diagnosis and treatment. A strong advocate of collaborative science, he has partnered with leading clinical specialists and secured numerous competitive research grants, including participation in major European Union initiatives such as SAFE-N-MEDTECH, EuroTransBio, and H2020 programs. Holding multiple patents in nanomedicine, Dr. Mangues’s innovative work bridges the gap between molecular oncology and clinical application. As a mentor and academic leader, he has supervised numerous doctoral theses and authored an extensive body of publications that have shaped contemporary cancer nanotherapy approaches. His achievements have been recognized through prestigious distinctions for research excellence and international scientific leadership. Dr. Mangues’s enduring impact on biomedical innovation is evident through 7,280 citations, 154 documents, and an h-index of 42, underscoring his influential role in advancing nanomedicine and targeted cancer therapy research.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Attolini, C. S.-O., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., Clevers, H., Sancho, E., Mangues, R., & Batlle, E. (2011). The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell, 8(5), 511–524. Cited by: 1,145

2. Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A. (2016). Recombinant pharmaceuticals from microbial cells: A 2015 update. Microbial Cell Factories, 15(1), 33. Cited by: 445

3. Esteller, M., Gonzalez, S., Risques, R. A., Marcuello, E., Mangues, R., Germa, J. R., Herman, J. G., Capellà, G., & Peinado, M. A. (2001). K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. Journal of Clinical Oncology, 19(2), 299–304. Cited by: 335

4. Guerrero, S., Casanova, I., Farré, L., Mazo, A., Capellà, G., & Mangues, R. (2000). K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene. Cancer Research, 60(23), 6750–6756. Cited by: 325

5. Ventura, S., Zurdo, J., Narayanan, S., Parreño, M., Mangues, R., Reif, B., Chiti, F., Giannoni, E., Dobson, C. M., & Serrano, L. (2004). Short amino acid stretches can mediate amyloid formation in globular proteins: The Src homology 3 (SH3) case. Proceedings of the National Academy of Sciences, 101(19), 7258–7263. Cited by: 301